Search

Your search keyword '"Van Laere, Koen"' showing total 1,677 results
Start Over Author "Van Laere, Koen"
1,677 results on '"Van Laere, Koen"'

18. Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid-PET

Author

De Meyer, Steffi, primary, Schaeverbeke, Jolien M, additional, Luckett, Emma S, additional, Reinartz, Mariska, additional, Blujdea, Elena R, additional, Cleynen, Isabelle, additional, Dupont, Patrick, additional, Van Laere, Koen, additional, Vanbrabant, Jeroen, additional, Stoops, Erik, additional, Vanmechelen, Eugeen, additional, di Molfetta, Guglielmo, additional, Zetterberg, Henrik, additional, Ashton, Nicholas J, additional, Teunissen, Charlotte E, additional, Poesen, Koen, additional, and Vandenberghe, Rik, additional

Published
2024
Full Text
View/download PDF

19. Synaptic density changes following electroconvulsive therapy: A longitudinal pilot study with PET-MR 11C-UCB-J imaging in late-life depression

Author

Laroy, Maarten, primary, Vande Casteele, Thomas, additional, Van Cauwenberge, Margot, additional, Koole, Michel, additional, Dupont, Patrick, additional, Sunaert, Stefan, additional, Van den Stock, Jan, additional, Sienaert, Pascal, additional, Van Laere, Koen, additional, Vandenbulcke, Mathieu, additional, Emsell, Louise, additional, and Bouckaert, Filip, additional

Published
2024
Full Text
View/download PDF

21. Regional accuracy of ZTE-based attenuation correction in static and dynamic brain PET/MR

Author

Schramm, Georg, Koole, Michel, Willekens, Stefanie M. A., Rezaei, Ahmadreza, Van Weehaeghe, Donatienne, Delso, Gaspar, Peeters, Ronald, Mertens, Nathalie, Nuyts, Johan, and Van Laere, Koen

Subjects
Physics - Medical Physics
Abstract

Accurate MR-based attenuation correction (MRAC) is essential for quantitative PET/MR imaging of the brain. In this study, we analyze the regional bias caused by MRAC based on Zero-Echo-Time MR images (ZTEAC) compared to CT-based AC (CTAC) in static and dynamic PET imaging. In addition the results are compared to the performance of the current default Atlas-based AC (AtlasAC) implemented in the GE SIGNA PET/MR. Methods: Thirty static [18F]FDG and 11 dynamic [18}F]PE2I acquisitions from a GE SIGNA PET/MR were reconstructed using ZTEAC (using a research tool, GE Healthcare), single-subject AtlasAC (the current default AC in GE's SIGNA PET/MR) and CTAC (from a PET/CT acquisition of the same day). In the 30 static [18F]FDG reconstructions, the bias caused by ZTEAC and AtlasAC in the mean uptake of 85 anatomical volumes of interest (VOIs) of the Hammers' atlas was analyzed in PMOD. For the 11 dynamic [18}F]PE2I reconstructions, the bias caused by ZTEAC and AtlasAC in the non displaceable binding potential BPnd in the striatum was calculated with cerebellum as the reference region and a simplified reference tissue model. Results: The regional bias caused by ZTEAC in the static [18F]FDG reconstructions ranged from -8.0% to +7.7% (mean 0.1%, SD 2.0%). For AtlasAC this bias ranged from -31.6% to +16.6% (mean -0.4%, SD 4.3%). The bias caused by AtlasAC showed a clear gradient in the cranio-caudal direction (-4.2% in the cerebellum, +6.6% in the left superior frontal gyrus). The bias in the striatal BPnd for the [18F]PE2I reconstructions ranged from -0.8% to +4.8% (mean 1.5%, SD 1.4%) using ZTEAC and from -0.6% to +9.4% using AtlasAC (mean 4.2%, SD 2.6%). Conclusion: ZTEAC provides excellent quantitative accuracy for static and dynamic brain PET/MR, comparable to CTAC, and is clearly superior to the default AtlasAC currently implemented in the GE SIGNA PET/MR., Comment: 23 pages in total, 7 figures, 1 table, 3 supplementary figures, 5 supplementary tables

Published
2018
Full Text
View/download PDF

26. Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature

Author

Deleu, Anne-Leen, Laenen, Annouschka, Decaluwé, Herbert, Weynand, Birgit, Dooms, Christophe, De Wever, Walter, Jentjens, Sander, Goffin, Karolien, Vansteenkiste, Johan, Van Laere, Koen, De Leyn, Paul, Nackaerts, Kristiaan, and Deroose, Christophe M.

Published
2022
Full Text
View/download PDF

29. MRI/PET Brain Imaging

Author

Schramm, Georg, Van Laere, Koen, Van Laar, Peter Jan, Koole, Michel, Dierckx, Rudi A. J. O., editor, Otte, Andreas, editor, de Vries, Erik F. J., editor, van Waarde, Aren, editor, and Leenders, Klaus L., editor

Published
2021
Full Text
View/download PDF

32. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

Author

Jansen, Willemijn J, Ossenkoppele, Rik, Tijms, Betty M, Fagan, Anne M, Hansson, Oskar, Klunk, William E, van der Flier, Wiesje M, Villemagne, Victor L, Frisoni, Giovanni B, Fleisher, Adam S, Lleó, Alberto, Mintun, Mark A, Wallin, Anders, Engelborghs, Sebastiaan, Na, Duk L, Chételat, Gäel, Molinuevo, José Luis, Landau, Susan M, Mattsson, Niklas, Kornhuber, Johannes, Sabri, Osama, Rowe, Christopher C, Parnetti, Lucilla, Popp, Julius, Fladby, Tormod, Jagust, William J, Aalten, Pauline, Lee, Dong Young, Vandenberghe, Rik, de Oliveira, Catarina Resende, Kapaki, Elisabeth, Froelich, Lutz, Ivanoiu, Adrian, Gabryelewicz, Tomasz, Verbeek, Marcel M, Sanchez-Juan, Páscual, Hildebrandt, Helmut, Camus, Vincent, Zboch, Marzena, Brooks, David J, Drzezga, Alexander, Rinne, Juha O, Newberg, Andrew, de Mendonça, Alexandre, Sarazin, Marie, Rabinovici, Gil D, Madsen, Karine, Kramberger, Milica G, Nordberg, Agneta, Mok, Vincent, Mroczko, Barbara, Wolk, David A, Meyer, Philipp T, Tsolaki, Magda, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Blennow, Kaj, van Buchem, Mark A, Cavedo, Enrica, Chen, Kewei, Chipi, Elena, Cohen, Ann D, Förster, Stefan, Fortea, Juan, Frederiksen, Kristian S, Freund-Levi, Yvonne, Gkatzima, Olymbia, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Johannsen, Peter, Klimkowicz-Mrowiec, Aleksandra, Köhler, Sebastian, Koglin, Norman, van Laere, Koen, de Leon, Mony, Lisetti, Viviana, Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Møllergård, Hanne M, Morris, John C, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Perera, Gayan, Peters, Oliver, and Ramakers, Inez HGB

Subjects
Health Services and Systems, Health Sciences, Acquired Cognitive Impairment, Alzheimer's Disease Related Dementias (ADRD), Neurosciences, Aging, Dementia, Brain Disorders, Behavioral and Social Science, Neurodegenerative, Alzheimer's Disease, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Neurological, Mental health, Aged, Alzheimer Disease, Amyloid beta-Peptides, Brain, Cognition Disorders, Cognitive Dysfunction, Cross-Sectional Studies, Female, Humans, Male, Memory, Episodic, Mental Status and Dementia Tests, Middle Aged, Positron-Emission Tomography, Reference Values, Amyloid Biomarker Study Group, Other Medical and Health Sciences, Psychology, Cognitive Sciences, Clinical sciences, Clinical and health psychology
Abstract

ImportanceCerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.ObjectiveTo investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.Design, setting, and participantsThis cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.Main outcomes and measuresGlobal cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.ResultsAmong 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P

Published
2018

40. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Author

Sanchez-Felipe, Lorena, Vercruysse, Thomas, Sharma, Sapna, Ma, Ji, Lemmens, Viktor, Van Looveren, Dominique, Arkalagud Javarappa, Mahadesh Prasad, Boudewijns, Robbert, Malengier-Devlies, Bert, Liesenborghs, Laurens, Kaptein, Suzanne J. F., De Keyzer, Carolien, Bervoets, Lindsey, Debaveye, Sarah, Rasulova, Madina, Seldeslachts, Laura, Li, Li-Hsin, Jansen, Sander, Yakass, Michael Bright, Verstrepen, Babs E., Böszörményi, Kinga P., Kiemenyi-Kayere, Gwendoline, van Driel, Nikki, Quaye, Osbourne, Zhang, Xin, ter Horst, Sebastiaan, Mishra, Niraj, Deboutte, Ward, Matthijnssens, Jelle, Coelmont, Lotte, Vandermeulen, Corinne, Heylen, Elisabeth, Vergote, Valentijn, Schols, Dominique, Wang, Zhongde, Bogers, Willy, Kuiken, Thijs, Verschoor, Ernst, Cawthorne, Christopher, Van Laere, Koen, Opdenakker, Ghislain, Vande Velde, Greetje, Weynand, Birgit, Teuwen, Dirk E., Matthys, Patrick, Neyts, Johan, Jan Thibaut, Hendrik, and Dallmeier, Kai

Published
2021
Full Text
View/download PDF

42. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment.

Author

Wang, Jie, Huang, Qi, He, Kun, Li, Junpeng, Guo, Tengfei, Yang, Yang, Lin, Zengping, Li, Songye, Vanderlinden, Greet, Huang, Yiyun, Van Laere, Koen, Guan, Yihui, Guo, Qihao, Ni, Ruiqing, Li, Binying, and Xie, Fang

Abstract

INTRODUCTION: Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the pathophysiological mechanism of Alzheimer's disease (AD). METHODS: Ten cognitively impaired (CI) individuals and 10 healthy controls (HCs) underwent [18F]SynVesT‐1 and [18F]PSS232 positron emission tomography (PET)/magnetic resonance to assess synaptic density and mGluR5 availability. The associations between mGluR5 availability and synaptic density were examined. A mediation analysis was performed to investigate the possible mediating effects of mGluR5 availability and synaptic loss on the relationship between amyloid deposition and cognition. RESULTS: CI patients exhibited lower mGluR5 availability and synaptic density in the medial temporal lobe than HCs. Regional synaptic density was closely associated with regional mGluR5 availability. mGluR5 availability and synaptic loss partially mediated the relationship between amyloid deposition and cognition. CONCLUSIONS: Reductions in mGluR5 availability and synaptic density exhibit similar spatial patterns in AD and are closely linked. Highlights: Cognitively impaired patients exhibited lower mGluR5 availability and synaptic density in the medial temporal lobe than HCs.Reductions in mGluR5 availability and synaptic density exhibit similar spatial patterns in AD.Regional synaptic density was closely associated with regional mGluR5 availability.mGluR5 availability and synaptic loss partially mediated the relationship between amyloid deposition and global cognition.With further research, modulating mGluR5 availability might be a potential therapeutic strategy for improving synaptic function in AD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group.

Author

Hobbs, Nicola Z., Papoutsi, Marina, Delva, Aline, Kinnunen, Kirsi M., Nakajima, Mitsuko, Van Laere, Koen, Vandenberghe, Wim, Herath, Priyantha, and Scahill, Rachael I.

Subjects
MAGNETIC resonance imaging, POSITRON emission tomography, HUNTINGTON disease, NUCLEAR magnetic resonance spectroscopy, PERFUSION imaging
Abstract

Neuroimaging is increasingly being included in clinical trials of Huntington's disease (HD) for a wide range of purposes from participant selection and safety monitoring, through to demonstration of disease modification. Selection of the appropriate modality and associated analysis tools requires careful consideration. On behalf of the EHDN Imaging Working Group, we present current opinion on the utility and future prospects for inclusion of neuroimaging in HD trials. Covering the key imaging modalities of structural-, functional- and diffusion- MRI, perfusion imaging, positron emission tomography, magnetic resonance spectroscopy, and magnetoencephalography, we address how neuroimaging can be used in HD trials to: 1) Aid patient selection, enrichment, stratification, and safety monitoring; 2) Demonstrate biodistribution, target engagement, and pharmacodynamics; 3) Provide evidence for disease modification; and 4) Understand brain re-organization following therapy. We also present the challenges of translating research methodology into clinical trial settings, including equipment requirements and cost, standardization of acquisition and analysis, patient burden and invasiveness, and interpretation of results. We conclude, that with appropriate consideration of modality, study design and analysis, imaging has huge potential to facilitate effective clinical trials in HD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Targeted STAT1 therapy for LZTR1‐driven peripheral nerve sheath tumor

Author

Ivanisevic, Tonci, primary, Steklov, Mikhail, additional, Lechat, Benoit, additional, Cawthorne, Christopher, additional, Gsell, Willy, additional, Velde, Greetje Vande, additional, Deroose, Christophe, additional, Van Laere, Koen, additional, Himmelreich, Uwe, additional, Sewduth, Raj N, additional, and Sablina, Anna A, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results